TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04795752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare System
Description: TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months. Beginning at 9 Months, subjects will receive an additional TearCare procedure when TBUT drops lower than Baseline or within 2 seconds of baseline AND/OR if OSDI worsens by at least 1 category.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At Month 6, subjects will be crossed over to the TearCare group and will receive one (1) TearCare procedure.
Study: NCT05707104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: NO. Exercises Targeted muscles Repetitions~1. Pelvic curl Abdominals, Hamstrings \& Quadriceps Femoris, Gluteus Maximums. 05~2. Chest lift Rectus Abdominus, Internal \& External Oblique Muscles 10~3. Leg lift supine Quadriceps Femoris, Internal \& External Oblique Muscles 10~4. Leg lift side Quadriceps Femoris, Posterior Spinal Group, Internal \& External Oblique Muscle 10~5. Leg full side Adductor Longus Brevis, Magnus , gracilis, Pectineus, muscles 10~6. Spine twist supine Abdominals,Quadriceps \& Hamstring group of Muscles 10~7. Chest lift with rotation Internal \& External Oblique, Rectus \& Transverses Abdominus Muscles 5 on each side~8. Back extension BACK EXTENSION Abdominal group, Gluteus Maximus \& Hamstrings Muscle 5 each side Rest between exercises 20 seconds Rest between set of exercises 45 to 60 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometrics exercises
Description: 1. SIDE TO SIDE ANKLE HOPS STANDING JUMP AND REACH FRONT CONE HOPS 2×15 2×15 5×6~2. SIDE TO SIDE ANKLE HOPS STANDING JUMP LATERAL JUMP BARRIER 2×15 5×6 2×15~3. DOUBLE LEG HOPS LATERAL CONE HOPS 5×8 2×12~4. DIAGONAL CONE HOPS LATERAL SPRINT 4×8 4×8~5. LATERAL CONE HOPS SINGLE LEG BOUNDING LATERAL JUMP SINGLE LEG 4×12 4×7 4×7~6. DIAGONAL CONE HOPS HEXAGONAL DRILL CONE HOPS WITH CHANGE OF DIRECTION SPRINT DOUBLE LEG HOPS LATERAL JUMP SINGLE LEG 2×12 2×12 4×6 3×8 4×6
Study: NCT04603339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme delivered via telehealth
Description: 12 week programme of;~1) Physiotherapy led aerobic and resistance exercise 2)1:1 Dietetics Counselling 3) Group Multidisciplinary Education Sessions
Study: NCT06241144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Information and communication technology -based health behavior change support system
Description: Information and communication technology -based health behavior change support system addition to conventional postpartum lifestyle education
Study: NCT05071742

Intervention type: GENETIC
Intervention: 2ml peripheral venous blood was collected to detect genetic genes
Description: Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection

Intervention type: GENETIC
Intervention: 2ml peripheral venous blood was collected to detect genetic genes
Description: Extraction of whole genome DNA: 2 mL of peripheral fasting venous blood was extracted, and edTA disodium was anticoagulant.The whole-genome DNA was extracted strictly in accordance with the instructions of the blood genomic DNA extraction kit (Beijing Tiagen Biochemical Technology Co., LTD., China), and the DNA concentration and purity were detected by nanodrop-1000 spectrophotometer (Thermo, USA). The DNA was diluted to 10 ng/μL and stored in a refrigerator at -80℃ for future use.~(2) Primer design and synthesis: (3) Gene polymorphism detection 4) Resin purification 5) Spot chip and mass spectrometry detection
Study: NCT05585099

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants will stand on lower body positive pressure treadmill and participate in walking exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will stand on lower body positive pressure treadmill and participate in walking exercise.
Study: NCT06204003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis/Hemp Isolate Extract
Description: Formulation: CBD (99%; 0.1% THC isolate)
Study: NCT05482776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity functional training
Description: HIFT is an exercise modality that emphasizes functional movements through exercises that involve a large amount of muscle mass and that can be adapted to the level of physical condition of each subject. Although it has similarities and is compared to HIIT, they are different.~In this discipline, functional exercises with an external load such as squats, pull-ups, or functional exercises with our own weight, are mixed with other aerobics such as running, rowing or cycling. This mix results in a high-intensity training that improves parameters of physical condition in general and performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classic training group
Description: This intervention consists of carrying out their conventional weekly physiotherapy training sessions where strength, coordination and balance are trained.
Study: NCT04974853

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cardio-complement
Description: Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.
Study: NCT05961124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
Study: NCT03595072

Intervention type: OTHER
Intervention: observation of VNS stimulation effects
Description: ECOGs will be recorded during VNS stimulation and inter stimulation periods
Study: NCT04920331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 140mg single intravenous administration (60 minutes)
Study: NCT05541380

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients

Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
Study: NCT05136326

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiation
Description: External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/sqm p.o. 5 days/week for 5 weeks
Study: NCT05270408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation (STARStim 8)
Description: Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation (STARStim 8)
Description: Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation (STARStim 8)
Description: Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
Study: NCT04973566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: HCQ will be administered orally.
Study: NCT05233462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized dose
Description: intrathecal anesthesia with 10 mg of bupivacaine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adjusted dose
Description: intrathecal anesthesia with 0.05 mg of bupivacaine par cm of patient's height
Study: NCT06061588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The use of virtual reality as an adjunct to routine treatment.
Study: NCT06076733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high definition-transcranial alternating current stimulation
Description: tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial alternating current stimulation
Description: Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
Study: NCT04771559

Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 antibody test
Description: 5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 antibody test
Description: 5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
Study: NCT04218539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 10mg Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 10mg Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 10mg Psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 25mg Diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 25mg Diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 25mg Diphenhydramine
Study: NCT05463250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartwatch
Description: Wearing a smartwatch and having access to its data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartwatch
Description: Wearing a smartwatch and having access to its data
Study: NCT05901506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a Nurse-led, Motivational Interview
Description: Family member participants will receive three counselling sessions: (1) preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions at weeks 2 \& 3, with 30-45 min, respectively. The sessions can be delivered via face-to-face, zoom meeting, or telephones. Before each session, the nurse will first assess the family member's readiness to engage in ACP based on the State to Change algorithm. Family members who have never thought about ACP will be in the pre-contemplation state. Family members who are willing to discuss end-of-life care will be in the contemplation state. Those who are ready to talk about end-of-life planning will be in the planning state. Readiness-based ACP goals will be established, and state-matched motivational interview counseling will be customized for each participant.
Study: NCT05585203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
Study: NCT06142474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily) 3 days before ventilator weaning in a ratio of 2:1. If the patients are allocated to SGLT2i treatment group, they will be further randomized equally to either empagliflozin- or dapagliflozin-treated group
Study: NCT05273411

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester
Description: Single-dose pharmacokinetic study over 4 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-hydroxybutyric acid
Description: Beta-hydroxybutyric acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,3-Butanediol
Description: 1,3-Butanediol
Study: NCT06033391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)
Description: GGOC was originally designed to challenge maladaptive beliefs that underline OCD symptoms in adult population. It was adapted to adolescent population. It consists of statements that are presented to the user, and that can portray either negative (I can't trust myself) or positive beliefs (I have a lot of good characteristics). Users have to respond by either pulling these towards Accept or Reject.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGN-AD (GG Neutral - Adolescents)
Description: it was designed to have a comparison group. It consists of neutral statements such as Madrid is a Spanish city, that ought not to produce changes in the direction of our hypothesis. These have to be Accepted or Rejected based on their veracity.
Study: NCT05679050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG Followed by FOLFIRINOX
Description: AG（every 28 days) Nab-paclitaxel 125 mg/m2 i.v. over 30 min, gemcitabine hydrochloride 1g/m2 i.v. over 30 min, D1, 8 and 15 ; FOLFIRINOX(every 42 days) Oxaliplatin: 65 mg/m2 i.v. over 2h on D1, 15, 29; Tetrahydrofolate: 400 mg/m2 i.v.2h on D1, 15, 29; Irinotecan: 150 mg/m2 i.v. over 90 min every 42 days on D1, 15, 29; 5-FU: 2400 mg/m2 i.v. over 46h /14 days on D1-3, 15-17, and 29-31; After one round of above therapy, patients achieving stable disease and above without disease progression or unacceptable toxicity underwent pancreatectomy within 4-8 weeks; Patients who did not achieve stable disease and above were treated another round , and patients who achieved stable disease and above underwent pancreatectomy at 4-8 weeks.~Following pancreatectomy, patients underwent AG regimen (2 rounds, 56 days) followed by FOLFIRINOX regimen (42 days) in the absence of disease progression or unacceptable toxicity, and AG and FOLFIRINOX dosing as the preoperative therapy.
Study: NCT05807204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
Study: NCT06340997

Intervention type: DEVICE
Group type: OTHER
Intervention: Transesophageal echocardiography
Description: * D.Echocardiography(Transthoracic and transesophageal):~* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).~The following conventional parameters were measured :~* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.~* Transesophageal echocardiogram (TEE) (to detect LAA function) .~* LAA flow velocity patterns by pulsed-wave Doppler~* Early diastolic emptying velocity~* Late diastolic emptying velocity or LAA contraction flow~* LAA filling velocity~* Systolic reflection waves~* Two-Dimensional- LAA fractional area change (LAAAC%)
Study: NCT06508840

Intervention type: OTHER
Intervention: Verbal Health Literacy training session
Description: Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff.

Intervention type: OTHER
Intervention: Verbal Health Literacy training session
Description: Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff.
Study: NCT05758428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: 14 Subjects enrolled will use one 3 mg/2.5 mL ampule for the 3 mg dose, subjects will receive a 3 mg ensifentrine single dose, followed by 3 mg repeated dose (twice daily, BID). On the dosing day (Day 1), subjects will receive a single dose of 3 mg ensifentrine. On Day 4, subjects will receive multiple doses of 3 mg ensifentrine BID for 3 days (Day 4 to Day 6), and a morning dose will be administered on Day 7.
Study: NCT05540964

Intervention type: OTHER
Intervention: Antiretroviral Therapy Interruption(ATI)
Description: Study participant that were previously infused with autologous genetically modified cell product will be taken off ART and followed closely by monitoring HIV rebound.